Demographic and clinical characteristics of SLE Registry patients
| Patients with clinician-recorded scores (N=2286) | Patients with estimated score categories (N=21 393) | Patients with both clinician-recorded and estimated score categories (N=1762) | Patients in model training cohort (N=1130) | ||
| Sex | Female | 2139 (93.6%) | 19 691 (92.0%) | 1650 (93.6%) | 1053 (93.2%) |
| Male | 147 (6.4%) | 1702 (8.0%) | 112 (6.4%) | 77 (6.8%) | |
| Race | Black | 602 (26.3%) | 4230 (19.8%) | 466 (26.4%) | 300 (26.5%) |
| White | 1284 (56.2%) | 12 236 (57.2%) | 1031 (58.5%) | 645 (57.1%) | |
| Other | 60 (2.6%) | 645 (3.0%) | 50 (2.8%) | 32 (2.8%) | |
| Unknown | 340 (14.9%) | 4282 (20.0%) | 215 (12.2%) | 153 (13.5%) | |
| Age, years | Mean (SD) | 50.0 (14.5) | 51.2 (15.0) | 48.3 (14.1) | 50.4 (14.5) |
| Duration of follow-up, years | Mean (SD) | 6.5 (1.4) | 6.4 (1.4) | 6.6 (1.3) | 6.7 (1.1) |
| Medical history (n, %) | Constitutional manifestations | 818 (35.8%) | 6271 (29.3%) | 530 (30.1%) | 414 (36.6%) |
| Musculoskeletal manifestations | 739 (32.3%) | 5953 (27.8%) | 518 (29.4%) | 377 (33.4%) | |
| Dermatologic manifestations | 260 (11.4%) | 1890 (8.8%) | 128 (7.3%) | 120 (10.6%) | |
| Renal manifestations | 375 (16.4%) | 3291 (15.4%) | 203 (11.5%) | 191 (16.9%) | |
| Neuropsychiatric manifestations | 464 (20.3%) | 3640 (17.0%) | 355 (20.1%) | 248 (21.9%) | |
| Pulmonary manifestations | 101 (4.4%) | 849 (4.0%) | 58 (3.3%) | 45 (4.0%) | |
| Gastrointestinal manifestations | 40 (1.7%) | 344 (1.6%) | 24 (1.4%) | 24 (2.1%) | |
| Cardiac manifestations | 40 (1.7%) | 307 (1.4%) | 18 (1.0%) | 22 (1.9%) | |
| Haematologic manifestations | 212 (9.3%) | 1540 (7.2%) | 119 (6.8%) | 98 (8.7%) | |
| Treatment history (n, %) | Azathioprine | 206 (9.0%) | 1112 (5.2%) | 117 (6.6%) | 104 (9.2%) |
| Belimumab | 389 (17.0%) | 866 (4.0%) | 177 (10.0%) | 199 (17.6%) | |
| Cyclophosphamide | 4 (0.2%) | 21 (0.1%) | 0 (0.0%) | 1 (0.1%) | |
| Ciclosporin | 2 (0.1%) | 25 (0.1%) | 3 (0.2%) | 1 (0.1%) | |
| Hydroxychloroquine | 1455 (63.6%) | 10 939 (51.1%) | 974 (55.3%) | 713 (63.1%) | |
| Methotrexate | 227 (9.9%) | 1638 (7.7%) | 155 (8.8%) | 121 (10.7%) | |
| Mycophenolate | 310 (13.6%) | 1572 (7.3%) | 166 (9.4%) | 146 (12.9%) | |
| Rituximab | 70 (3.1%) | 238 (1.1%) | 27 (1.5%) | 45 (4.0%) | |
| Sirolimus | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Tacrolimus | 4 (0.2%) | 41 (0.2%) | 6 (0.3%) | 2 (0.2%) | |
| Ustekinumab | 0 (0.0%) | 9 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Glucocorticoids | 1296 (56.7%) | 9191 (43.0%) | 912 (51.8%) | 661 (58.5%) | |
| Prescription NSAIDs | 570 (24.9%) | 4300 (20.1%) | 408 (23.2%) | 282 (25.0%) |
NSAIDs, non-steroidal anti-inflammatory drugs.